Apellis Pharmaceuticals has announced US FDA acceptance of the supplemental new drug application (sNDA) and the granting of ...

Pharmaceuticals announced that the U.S. Food and Drug Administration, FDA, has accepted and granted Priority Review designation ...

Apellis' Empaveli receives FDA Priority Review for rare kidney diseases C3G and IC-MPGN. Phase 3 data show strong efficacy in proteinuria reduction.

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Free Report) has received an average recommendation of “Moderate Buy” from ...

We recently compiled a list of the 12 Most Promising Biotech Stocks According to Wall Street Analysts. In this article, we ...

Signaturefd LLC increased its position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) by 357.2% during the 4th ...

JP Morgan sees steady growth for Apellis' Syfovre, lowering the price target to $45. Syfovre sales hit $167.8M in Q4, with over 94,000 doses delivered.

Novartis' Fabhalta has become the first treatment approved by the FDA for the ultra-rare kidney disease C3G. But analysts ...

In the United States, the market has experienced a 3.5% decline over the last week, yet it remains up by 5.8% over the past year with earnings expected to grow annually by 14%. In this context of ...

Morgan Stanley analyst Judah Frommer notes that Novartis (NVS) has received FDA approval for Fabhalta for C3G. The label comes with a few ...

Analysts' ratings for Apellis Pharmaceuticals (NASDAQ:APLS) over the last quarter vary from bullish to bearish, as provided by 6 analysts. Summarizing their recent assessments, the table below ...